Valuation: Ovid Therapeutics Inc.

Market Cap 476M 417M 385M 360M 675M 44.9B 689M 4.62B 1.79B 22.19B 1.79B 1.75B 76.94B P/E 2026 *
-5.28x
P/E 2027 * -4.78x
Enterprise Value 476M 417M 385M 360M 675M 44.9B 689M 4.62B 1.79B 22.19B 1.79B 1.75B 76.94B EV / Sales 2026 *
4,427x
EV / Sales 2027 * 2,856x
Free-Float
93.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day+5.37%
1 week+12.33%
Current month-6.59%
1 month+4.08%
3 months+3.66%
6 months+43.26%
Current year+56.44%
1 week 2.19
Extreme 2.19
2.6
1 month 2.16
Extreme 2.162
2.77
Current year 1.36
Extreme 1.36
3.1
1 year 0.3
Extreme 0.3001
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.42
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 31/12/2025
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer 60 01/12/2025
Director TitleAgeSince
Chairman 72 31/03/2014
Director/Board Member 73 29/09/2015
Director/Board Member 81 22/11/2015
Date Insider Type Main position Quantity % Market Cap.
06-14Free

Director

130,000 0.0697%
04-06Free

Director

17,578 0.0133%
04-06Free

Director

8,789 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
+5.37%+12.33%+643.44%-25.22% 476M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.64%+5.53%+102.37%+111.76% 22.68B
Weighted average by Cap. +0.27%+5.15%+49.75%+119.85%

Financials

2026 *2027 *
Net sales 108K 94.26K 86.88K 81.34K 153K 10.14M 156K 1.04M 404K 5.01M 404K 395K 17.38M 167K 146K 135K 126K 236K 15.72M 241K 1.62M 626K 7.77M 626K 612K 26.94M
Net income -77.12M -67.62M -62.33M -58.35M -109M -7.28B -112M -749M -290M -3.6B -290M -283M -12.47B -89.84M -78.77M -72.61M -67.98M -127M -8.47B -130M -873M -338M -4.19B -337M -330M -14.52B
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
26/06/26 US$2.550 +5.37% 22,546,134
25/06/26 US$2.420 -3.20% 2,140,132
24/06/26 US$2.500 +7.76% 2,805,102
23/06/26 US$2.320 +3.11% 2,421,898
22/06/26 US$2.250 -0.88% 2,568,840
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.550USD
Average target price
5.471USD
Spread / Average Target
+114.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock